Mercaptopurine Anhydrous

Mercaptopurine Anhydrous

SCHEMBL8844

Sc1ncnc2nc[nH]c12

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPAT

The experimentally established mechanism targets of Mercaptopurine Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.57
PI4KA P42356 2/20 0.57
PI4K2B Q8TCG2 2/20 0.57
PI4K2A Q9BTU6 2/20 0.57
PI4KB Q9UBF8 2/20 0.57
LRRK2 Q5S007 2/20 0.57
DRD3 P35462 1/20 0.57
XDH P47989 1/20 0.57
G6PD P11413 1/20 0.55
PDPK1 O15530 3/20 0.52
TP53 P04637 2/20 0.52
CHEK1 O14757 2/20 0.52
AURKA O14965 1/20 0.52
CHEK2 O96017 1/20 0.52
HSP90AA1 P07900 1/20 0.52
HSP90AB1 P08238 1/20 0.52
PRKACA P17612 1/20 0.52
CCNE1 P24864 1/20 0.52
CDK2 P24941 1/20 0.52
MARK3 P27448 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mercaptopurine Anhydrous SCHEMBL29684795 1.00 LMNA (0.57) LMNAPI4KAPI4K2BPI4K2API4KB
Mercaptopurine Anhydrous SCHEMBL31379732 0.98 LMNA (0.55) LMNAPI4KAPI4K2BPI4K2API4KB
Mercaptopurine Anhydrous SCHEMBL5144254 0.98 LMNA (0.55) LMNAPI4KAPI4K2BPI4K2API4KB
Mercaptopurine Anhydrous SCHEMBL734088 0.98 LMNA (0.55) LMNAPI4KAPI4K2BPI4K2API4KB
Mercaptopurine Anhydrous SCHEMBL30834915 0.98 LMNA (0.55) LMNAPI4KAPI4K2BPI4K2API4KB
Mercaptopurine Anhydrous SCHEMBL28474534 0.89 HSD17B10 (0.50) LMNAPI4KAPI4K2BPI4K2API4KB
Mercaptopurine Anhydrous SCHEMBL1820743 0.84 PI4KA (0.43) LMNAPI4KAPI4K2BPI4K2API4KB
Mercaptopurine Anhydrous SCHEMBL4447615 0.83 MKNK1 (0.47) LMNAPI4KAPI4K2BPI4K2API4KB
Mercaptopurine Anhydrous SCHEMBL5534039 0.82 ALDH1A1 (0.44) LMNAPI4KAPI4K2BPI4K2API4KB
SCHEMBL29559610 0.77 LMNA (0.57) LMNAPI4KAPI4K2BPI4K2API4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 101528 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4748859-A2 CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF The Regents of the University of California (US) 2026-05-27 EP claimed
EP-4746876-A1 UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE SYNTHASE (UGCG) INHIBITORS IN THE TREATMENT OF CANCER Katholieke Universiteit Leuven (BE) 2026-05-27 EP claimed
CN-116209439-B Cereblon protein modulators Saint Jude Children's Research Hospital Ltd. (US) 2026-05-26 CN claimed
US-20260138973-A1 SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE SITRYX THERAPEUTICS LTD (GB) 2026-05-21 US claimed
WO-2026106497-A2 FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) 2026-05-21 WO claimed
US-20260137650-A1 MODULATORS OF RAR RELATED ORPHAN RECEPTORS (RORs) 11949098 CANADA INC (CA) 2026-05-21 US claimed
US-20260137700-A1 PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE SK BIOPHARMACEUTICALS CO LTD (KR) 2026-05-21 US claimed
US-20260137680-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LTD (GB) 2026-05-21 US claimed
EP-4743490-A1 HUMANIZED ANTI-CD7 ANTIBODY Christian-Albrechts-Universität zu Kiel (DE) 2026-05-20 EP claimed
CN-122056884-A Methods of treating pancreatic cancer 坎莫森特里克斯公司 2026-05-19 CN claimed
EP-0009154-B1 COMPLEXES OF 9-HYDROXYALKYL-PURINES, PROCESSES FOR PREPARING THEM AND THERAPEUTICAL COMPOSITIONS CONTAINING THE COMPLEXES AS ACTIVE INGREDIENTS Newport Pharmaceuticals International, Inc. (US) 1982-12-08 EP claimed
EP-0038541-A1 Novel prodrugs of biologically active agents containing mercapto groups, process for preparing and therapeutically effective composition containing the same MERCK & CO. INC. (US) 1981-10-28 EP claimed
EP-0036138-A2 Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide MERCK & CO. INC. (US) 1981-09-23 EP claimed
US-4291024-A ANTICANCER AGENTS UNIVERSITY OF RHODE ISLAND 1981-09-22 US claimed
EP-0033341-A1 CYTOTOXIC NUCLEOSIDE-CORTICOSTEROID PHOSPHODIESTERS Research Corporation (US) 1981-08-12 EP claimed
US-4283394-A ANTICARCINOGENIC AGENTS RESEARCH CORPORATION (US) 1981-08-11 US claimed
WO-1981000410-A1 CYTOTOXIC NUCLEOSIDE-CORTICOSTEROID PHOSPHODIESTERS RESEARCH CORP (US) 1981-02-19 WO claimed
EP-0007206-A1 Phenethanolamines, their formulations, preparation and use ELI LILLY AND COMPANY (US) 1980-01-23 EP claimed
US-4147767-A CROSSLINKED WITH FORMALDEHYDE OR GLUTARALDEHYDE MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1979-04-03 US claimed
US-4108804-A Process for preparation of chromatography solid supports comprising a nucleic acid base-epoxy group containing porous gel SEITA TORU 1978-08-22 US claimed